Jentadueto (Metformin Hydrochloride, Linagliptin)

Jentadueto is indicated for the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia.

• Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose levels.
• Inadequate control on monotherapy: provides additional glucose‑lowering effect when metformin alone is insufficient.
• Metabolic syndrome (as part of diabetes management): helps reduce insulin resistance and supports overall metabolic balance.

• Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while linagliptin selectively inhibits dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin levels (GLP‑1 and GIP) that promote glucose‑dependent insulin secretion and suppress glucagon release, together resulting in improved glycemic control.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
• Headache or dizziness.
• Mild hypoglycemia when combined with other glucose‑lowering agents.
• Metallic taste.
• Weight loss.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening metabolic complication.
• Severe hypoglycemia, especially with concomitant sulfonylureas or insulin.
• Acute pancreatitis.
• Hepatic dysfunction or elevated liver enzymes.
• Severe allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for adverse events.

• Renal function: assess baseline renal status and monitor regularly; avoid in severe impairment.
• Hepatic disease: use with caution and monitor liver enzymes.
• Risk of lactic acidosis: contraindicated in patients with conditions predisposing to hypoxia.
• Pregnancy and lactation: evaluate risk–benefit; limited safety data available.
• Concomitant sulfonylureas or insulin: increased risk of hypoglycemia; dose adjustments may be needed.
• Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Jentadueto may interact with several medicines that affect glucose metabolism or renal function.

Major Interactions (Avoid)

• Iodinated contrast agents in patients with reduced renal function: may precipitate acute kidney injury.
• Co‑administration with another DPP‑4 inhibitor: additive inhibition can increase risk of adverse effects.
• Strong CYP3A4 inhibitors (although linagliptin has minimal CYP metabolism): may increase drug exposure.

Moderate Interactions (Monitor Closely)

• Sulfonylureas or insulin: heightened hypoglycemia risk; monitor blood glucose.
• Diuretics (e.g., thiazides): may affect glucose control.
• Corticosteroids: can reduce antidiabetic efficacy.
• Cationic anti‑arrhythmics (e.g., amiodarone): may increase metformin plasma levels.
• NSAIDs: may impair renal function, influencing metformin clearance.